MCET News MultiCell Technologies Posts Journal Article on Research Leading to Company's Recent Patent Application on Novel Cancer Treatment
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class
drugs based on advanced immune system modulation and other proprietary
technologies, has posted a scientific article published in the Journal
of Immunology on its web site describing the application of the Company’s
unique immune system modulation technology to treat cancer.
The Company has made the article available to investors in the wake of
its recent filing of a key patent relating to the application of its
immune system-based technology to treat or control a range of malignant
cancer tumors. MultiCell’s drug candidate and
proprietary technology MCT-465 is a key element of anti-tumor process
discussed in the journal article and the patent application.
MultiCell is an innovator in the science of modulating the human immune
system with unique platform technologies, focusing on the development of
breakthrough drugs to treat serious autoimmune diseases, including
multiple sclerosis and type-1 diabetes, as well as influenza and cancer.
Currently, the market for therapies that address these diseases is
estimated at $8 billion worldwide.
“Together with our industry leading
collaborators, MultiCell has managed to discover new ways to understand
and potentially treat widespread malignant tumors in cancer patients
around the world,” said Dr. Stephen Chang,
Chief Executive Officer of MultiCell Technologies. “The
research on MCT-465 and our other technologies covered in the Journal of
Immunology article further validates our scientific and business model
to develop drug candidates that work with the body's own immune system
to deliver an entirely new generation of disease-specific
immunotherapeutics.”
The Company's technology platforms include TLR and T-cell targeting to
modulate both the innate and adaptive immune systems, thus enabling the
creation of advanced drug candidates that stimulate or suppress the
immune system via disease-specific targeting.
The article, “Immunologic Control of Tumors
by In Vivo Fcy Receptor-Targeted Antigen Loading in Conjunction with
Double-Stranded RNA-Mediated Immune Modulation,”
details how MCET and its collaborators showed that the Company’s
technology resulted in control of tumor growth by modulating the immune
system.
The Journal of Immunology is owned and published by The American
Association of Immunologists. The journal is cited more than any other
immunology journal.
Recently, MultiCell filed the patent application entitled, "Methods for
Tumor Control and Treatment by Loading an Antigen Presenting Cell,"
which covers the use of MultiCell's proprietary dsRNA and Toll-like
receptor (TLR) technology platform to combat malignant tumors in human
patients.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company
committed to the development of breakthrough therapeutics based on a
portfolio of therapeutic candidates and patented drug development
technology. MultiCell's drug development program is focused on
modulation of the immune system. The Company's lead drug candidates
include drugs to treat MS-related chronic fatigue, relapsing-remitting
multiple sclerosis, type-1 diabetes and infectious disease. The Company
also holds unique cell-based technology for use in drug discovery
screening applications, and is a leading producer of the cell lines
needed by the biotechnology industry to develop new drugs and
therapeutics. For more information about MultiCell Technologies, please
visit http://www.MultiCelltech.com.
For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell.
For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html.
To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html.
To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.
Any statements in this press release about MultiCell's expectations,
beliefs, plans, objectives, assumptions or future events or performance
are not historical facts and are forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
These statements are often, but not always, made through the use of
words or phrases such as "believe," "will,""expect," "anticipate,"
"estimate," "intend," "plan," "forecast," "could" and "would." Examples
of such forward-looking statements include statements regarding
developing products that address unmet medical needs. MultiCell bases
these forward-looking statements on current expectations about future
events. They involve known and unknown risks, uncertainties and
assumptions that may cause actual results, levels of activity,
performance or achievements to differ materially from those expressed or
implied by any forward-looking statement. Some of the risks,
uncertainties and assumptions that could cause actual results to differ
materially from estimates or projections in the forward-looking
statement include, but are not limited to, the risk that we might not
achieve our anticipated clinical development milestones, receive
regulatory approval, or successfully commercialize our lead drug
candidates as expected, the market for our products will not grow as
expected, and the risk that our products will not achieve expectations.
For additional information about risks and uncertainties MultiCell
faces, see documents MultiCell files with the SEC, including MultiCell's
report on Form 10-KSB for the fiscal year ended November 30, 2005, and
all our quarterly and other periodic SEC filings. MultiCell claims the
protection of the safe harbor for forward-looking statements under the
Act and each assume no obligation and expressly disclaim any duty to
update any forward-looking statement to reflect events or circumstances
after the date of this news release or to reflect the occurrence of
subsequent events.
